clarithromycin

clarithromycin is a lipid of Polyketides (PK) class. Clarithromycin is associated with abnormalities such as Helicobacter Pylori Infection, Infection, Coinfection, Gastritis and Peptic Ulcer. The involved functions are known as Point Mutation, Increased Sensitivy, Bacterial resistance, urease activity and Mutation. Clarithromycin often locates in Blood, Gastric mucosa, Biopsy sample, Respiratory System and Entire gastrointestinal tract. The associated genes with clarithromycin are Genes, rRNA, rRNA Operon, Genome, HM13 gene and GDF15 gene. The related lipids are 9,11-linoleic acid, Steroids, Lysophosphatidylcholines, Lipopolysaccharides and 4-hydroxycholesterol. The related experimental models are Mouse Model, Knock-out and Experimental Pneumococcal Meningitis.

Cross Reference

Introduction

To understand associated biological information of clarithromycin, we collected biological information of abnormalities, associated pathways, cellular/molecular locations, biological functions, related genes/proteins, lipids and common seen animal/experimental models with organized paragraphs from literatures.

What diseases are associated with clarithromycin?

clarithromycin is suspected in Infection, Helicobacter Pylori Infection, Pneumonia, Respiratory Tract Infections, PARKINSON DISEASE, LATE-ONSET, Community acquired pneumonia and other diseases in descending order of the highest number of associated sentences.

Related references are mostly published in these journals:

Disease Cross reference Weighted score Related literature
Loading... please refresh the page if content is not showing up.

Possible diseases from mapped MeSH terms on references

We collected disease MeSH terms mapped to the references associated with clarithromycin

MeSH term MeSH ID Detail
Periodontitis D010518 22 associated lipids
Fibrosis D005355 23 associated lipids
Cardiovascular Diseases D002318 24 associated lipids
Stomach Neoplasms D013274 24 associated lipids
Genetic Predisposition to Disease D020022 24 associated lipids
Pseudomonas Infections D011552 25 associated lipids
Nasal Polyps D009298 26 associated lipids
Gastrointestinal Hemorrhage D006471 27 associated lipids
Angina Pectoris D000787 27 associated lipids
Gastritis D005756 27 associated lipids
Endometriosis D004715 29 associated lipids
Drug Eruptions D003875 30 associated lipids
Proteinuria D011507 30 associated lipids
Diarrhea D003967 32 associated lipids
Ventricular Dysfunction, Left D018487 33 associated lipids
Neurotoxicity Syndromes D020258 34 associated lipids
Acute Kidney Injury D058186 34 associated lipids
Fever D005334 35 associated lipids
Heart Failure D006333 36 associated lipids
Lung Diseases D008171 37 associated lipids
Arthritis D001168 41 associated lipids
Arrhythmias, Cardiac D001145 42 associated lipids
Lupus Erythematosus, Systemic D008180 43 associated lipids
Psoriasis D011565 47 associated lipids
Parkinson Disease D010300 53 associated lipids
Diabetes Mellitus, Type 1 D003922 56 associated lipids
Pain D010146 64 associated lipids
Cystic Fibrosis D003550 65 associated lipids
Mammary Neoplasms, Experimental D008325 67 associated lipids
Colitis D003092 69 associated lipids
Hyperlipidemias D006949 73 associated lipids
Stomach Ulcer D013276 75 associated lipids
Arteriosclerosis D001161 86 associated lipids
Diabetes Mellitus, Type 2 D003924 87 associated lipids
Hypercholesterolemia D006937 91 associated lipids
Insulin Resistance D007333 99 associated lipids
Cell Transformation, Neoplastic D002471 126 associated lipids
Hemolysis D006461 131 associated lipids
Carcinoma, Hepatocellular D006528 140 associated lipids
Adenocarcinoma D000230 166 associated lipids
Lung Neoplasms D008175 171 associated lipids
Body Weight D001835 333 associated lipids
Per page 10 20 50 100 | Total 242

PubChem Associated disorders and diseases

What pathways are associated with clarithromycin

There are no associated biomedical information in the current reference collection.

PubChem Biomolecular Interactions and Pathways

Link to PubChem Biomolecular Interactions and Pathways

What cellular locations are associated with clarithromycin?

Related references are published most in these journals:

Location Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

What functions are associated with clarithromycin?


Related references are published most in these journals:

Function Cross reference Weighted score Related literatures

What lipids are associated with clarithromycin?

Related references are published most in these journals:

Lipid concept Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

What genes are associated with clarithromycin?

Related references are published most in these journals:


Gene Cross reference Weighted score Related literatures

What common seen animal models are associated with clarithromycin?

Mouse Model

Mouse Model are used in the study 'Inflammation provoked by Mycoplasma pneumoniae extract: implications for combination treatment with clarithromycin and dexamethasone.' (Hirao S et al., 2011), Mouse Model are used in the study 'Tolerance and pharmacokinetic interactions of rifabutin and clarithromycin in human immunodeficiency virus-infected volunteers.' (Hafner R et al., 1998), Mouse Model are used in the study 'Clarithromycin attenuates mastectomy-induced acute inflammatory response.' (Chow LW et al., 2000) and Mouse Model are used in the study 'In vitro and in vivo influence of adjunct clarithromycin on the treatment of mucoid Pseudomonas aeruginosa.' (Bui KQ et al., 2000).

Knock-out

Knock-out are used in the study 'Intrinsic macrolide resistance in Mycobacterium smegmatis is conferred by a novel erm gene, erm(38).' (Nash KA, 2003).

Experimental Pneumococcal Meningitis

Experimental Pneumococcal Meningitis are used in the study 'Failure of treatment for chronic Mycobacterium abscessus meningitis despite adequate clarithromycin levels in cerebrospinal fluid.' (Maniu CV et al., 2001).

Related references are published most in these journals:

Model Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

NCBI Entrez Crosslinks

All references with clarithromycin

Download all related citations
Per page 10 20 50 100 | Total 7636
Authors Title Published Journal PubMed Link
Katelaris PH et al. Randomized trial of omeprazole and metronidazole with amoxycillin or clarithromycin for Helicobacter pylori eradication, in a region of high primary metronidazole resistance: the HERO study. 2000 Aliment. Pharmacol. Ther. pmid:10848659
Ammon S et al. Influence of age on the steady state disposition of drugs commonly used for the eradication of Helicobacter pylori. 2000 Aliment. Pharmacol. Ther. pmid:10848660
Huang J et al. Randomised controlled trial: sequential vs. standard triple therapy for Helicobacter pylori infection in Chinese children-a multicentre, open-labelled study. 2013 Aliment. Pharmacol. Ther. pmid:24117692
Molina-Infante J et al. Clinical trial: clarithromycin vs. levofloxacin in first-line triple and sequential regimens for Helicobacter pylori eradication. 2010 Aliment. Pharmacol. Ther. pmid:20180787
Gisbert JP et al. 7-day rescue therapy with ranitidine bismuth citrate after Helicobacter pylori treatment failure. 2005 Aliment. Pharmacol. Ther. pmid:15882246
Nista EC et al. Moxifloxacin-based strategies for first-line treatment of Helicobacter pylori infection. 2005 Aliment. Pharmacol. Ther. pmid:15882245
Lehmann FS et al. Effect of ornidazole and clarithromycin resistance on eradication of Helicobacter pylori in peptic ulcer disease. 2000 Aliment. Pharmacol. Ther. pmid:10735923
Miwa H et al. Cure of Helicobacter pylori infection does not improve symptoms in non-ulcer dyspepsia patients-a double-blind placebo-controlled study. 2000 Aliment. Pharmacol. Ther. pmid:10735925
Malfertheiner P et al. Helicobacter pylori eradication is beneficial in the treatment of functional dyspepsia. 2003 Aliment. Pharmacol. Ther. pmid:12969088
Huang J and Hunt RH The importance of clarithromycin dose in the management of Helicobacter pylori infection: a meta-analysis of triple therapies with a proton pump inhibitor, clarithromycin and amoxycillin or metronidazole. 1999 Aliment. Pharmacol. Ther. pmid:10383500
Miwa H et al. Impact of rabeprazole, a new proton pump inhibitor, in triple therapy for Helicobacter pylori infection-comparison with omeprazole and lansoprazole. 1999 Aliment. Pharmacol. Ther. pmid:10383502
Wong BC et al. Rabeprazole-based 3-day and 7-day triple therapy vs. omeprazole-based 7-day triple therapy for the treatment of Helicobacter pylori infection. 2001 Aliment. Pharmacol. Ther. pmid:11736727
Koivisto TT et al. Primary Helicobacter pylori resistance to metronidazole and clarithromycin in the Finnish population. 2004 Aliment. Pharmacol. Ther. pmid:15113368
Dobrilla G et al. Ranitidine bismuth citrate with either clarithromycin 1 g/day or 1.5 g/day is equally effective in the eradication of H. pylori and healing of duodenal ulcer. 1998 Aliment. Pharmacol. Ther. pmid:9692703
Perri F et al. Randomized study of different 'second-line' therapies for Helicobacter pylori infection after failure of the standard 'Maastricht triple therapy'. 2003 Aliment. Pharmacol. Ther. pmid:14535875
Sheu BS et al. Esomeprazole 40 mg twice daily in triple therapy and the efficacy of Helicobacter pylori eradication related to CYP2C19 metabolism. 2005 Aliment. Pharmacol. Ther. pmid:15691303
Zullo A et al. Clarithromycin or levofloxacin in the sequential therapy for H. pylori eradication? 2010 Aliment. Pharmacol. Ther. pmid:20518756
Gisbert JP and Pajares JM Review article: Helicobacter pylori "rescue" regimen when proton pump inhibitor-based triple therapies fail. 2002 Aliment. Pharmacol. Ther. pmid:12030945
Laine L and Dhir V Helicobacter pylori eradication does not worsen quality of life related to reflux symptoms: a prospective trial. 2002 Aliment. Pharmacol. Ther. pmid:12030957
Vallve M et al. Single vs. double dose of a proton pump inhibitor in triple therapy for Helicobacter pylori eradication: a meta-analysis. 2002 Aliment. Pharmacol. Ther. pmid:12030958